Chemed Corp (CHE)vsEli Lilly and Company (LLY)
CHE
Chemed Corp
$515.97
+0.31%
HEALTHCARE · Cap: $6.78B
LLY
Eli Lilly and Company
$1,137.76
+1.98%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 2970% more annual revenue ($79.67B vs $2.60B). LLY leads profitability with a 33.5% profit margin vs 10.6%. LLY appears more attractively valued with a PEG of 1.11. LLY earns a higher WallStSmart Score of 76/100 (B+).
CHE
Buy63
out of 100
Grade: C+
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Safe zone — low bankruptcy risk
Earnings expanding 43.7% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Trading at 8.1x book value
Weak financial health signals
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CHE
The strongest argument for CHE centers on Return on Equity, Altman Z-Score, EPS Growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : CHE
The primary concerns for CHE are PEG Ratio, P/E Ratio, Price/Book.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
CHE profiles as a value stock while LLY is a growth play — different risk/reward profiles.
CHE carries more volatility with a beta of 0.51 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 63/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Chemed Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?